This clinical trial focuses on children who have received a kidney transplant. The study is investigating the use of a medication called tacrolimus, which is commonly used to help prevent the body from rejecting a new kidney. The trial aims to personalize the treatment for each child by using a special method to calculate the right dose of tacrolimus for them. This method involves a dosing algorithm, which is a type of formula that helps doctors decide how much medication a child should take.
In this study, children will receive one of several forms of tacrolimus, including PROGRAF capsules, Modigraf granules for oral suspension, and Envarsus prolonged-release tablets. These medications are all taken by mouth. The goal is to find the best way to give tacrolimus so that it works effectively and safely for each child. The study will monitor how well the children maintain the right levels of tacrolimus in their blood, especially in the first few days after their kidney transplant.
The purpose of the study is to improve the way tacrolimus is given to children who have had a kidney transplant, making it more tailored to their individual needs. This approach hopes to ensure that each child receives the most effective dose with the least risk of side effects. The study will last for a period of time, during which the children will be closely observed to see how well the personalized dosing works for them.
The Netherlands 
